This article is more than 5 years old. Information may no longer be current.

NuVasive launches next generation biologics technology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NuVasive Inc. announced the U.S. launch of its AttraX Putty.

AttraX Putty, which reportedly has been used globally since 2011 and received FDA 510(k) clearance in 2015, is a synthetic, osteoconductive bone-void filler used for the repair of bone defects. Featuring a unique biotextured surface, AttraX Putty is designed to help drive regeneration of bone at the implanted site.

“We are excited to officially launch AttraX Putty for surgical use in the [United States] U.S. and expect it to be a cornerstone of our expanding biologics portfolio,” Pat Miles, president and chief operating officer at NuVasive, said in a press release. “AttraX Putty has helped improve outcomes for more than 20,000 spine patients worldwide, and we are pleased to now bring this biologic to market in the United States. Today’s launch is another example of NuVasive’s continued commitment to invest in industry-leading innovation that deliver the best possible patient outcomes.”

Reference:

www.nuvasive.com